Drugs / BBO-10203
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06917079 | Mar 2025 → Aug 2027 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Recruiting | No outcome recorded |
| Phase 1 | NCT06625775 | Oct 2024 → Nov 2028 expected | HER2 positive breast carcinoma, colorectal cancer, hormone receptor-positive breast cancer, lung carcinoma | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Recruiting | No outcome recorded |
| Phase 1 | NCT06343402 | May 2024 → Apr 2031 expected | non-small cell lung carcinoma | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBO-10203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06343402 ↗ |
| Route | Oral | “BBO-10203 orally once daily” NCT06625775 ↗ |